Manufacturer and distributor of immunotherapeutic agents. The firm is developing a cancer vaccine to treat malignant melanoma by combining cell wall skeleton and monophosphoryl lipid A (MPL) with a tumor antigen. The firm is also planning to conduct a human cancer trial to test the safety of a new synthetic compound against cardiac reperfusion injury. Products are sold to multiple industries. The bulk of revenue is derived from activity in the biotechnology industry. This company was capitalized by corporate investment, private investment and venture capital. Products include malignant melanoma cancer vaccines, vaccine adjuvants.